Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie Adds Dr. John M. Carethers as Independent Director, Expanding Board to 13

Neutral Impact 2 of 5 leadership Written later

AbbVie expanded its Board of Directors from twelve to thirteen seats on October 14, 2026, and appointed Dr. John M. Carethers as a Class II director. The Board determined he is independent under NYSE standards, and he joins the Public Policy and Sustainability Committee.

Key points

  • Board size increased from twelve directors to thirteen on October 14, 2026
  • Dr. John M. Carethers appointed as Class II director; serves as Vice Chancellor for Health Sciences at UC San Diego
  • Carethers named to the Public Policy and Sustainability Committee and deemed independent under NYSE rules
  • Compensation as an independent director is disclosed in Exhibit 10.5 to the Form 10-Q for the quarter ended March 31, 2025

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECOct 15, 2026, 4:00 PM ET
Accession number0001104659-26-116227

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.